Antifungals targeting pantothenate phosphorylation
靶向泛酸磷酸化的抗真菌药
基本信息
- 批准号:10696567
- 负责人:
- 金额:$ 29.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAmphotericin BAnabolismAnimal ModelAntifungal AgentsAspergillosisAspergillusAspergillus fumigatusAzolesBindingBiochemicalBiologicalCandidaCandida albicansCandidiasisCatalytic DomainCell SurvivalCessation of lifeChemicalsClinicalCoenzyme AComplexCryptococcusDataDevelopmentDisseminated candidiasisDoseDrug KineticsDrug resistanceEconomic BurdenEconomicsEnzymesErgosterolFluconazoleGenerationsGenetic studyGoalsHealthcareHospitalsHumanHuman Cell LineImmunocompromised HostIn VitroInfectionLeadLength of StayLibrariesManuscriptsMapsMetabolicMetabolic PathwayModelingMorbidity - disease rateMulti-Drug ResistanceMusMycosesNosocomial InfectionsOralOrganismPantothenate kinasePantothenic AcidPathway interactionsPatient-Focused OutcomesPatientsPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPharmacology StudyPhasePhosphorylationPneumocystisPolyenesPropertyPublic HealthRegimenRelationship-BuildingResistanceSaccharomyces cerevisiaeSafetySolubilityStructureStructure-Activity RelationshipUnited StatesVitaminsanalogcare burdencofactorcytotoxicityeffective therapyefficacy evaluationexperiencefungushigh throughput screeningimprovedin vitro activityin vivoindexinginhibitorkinase inhibitorlead candidatemetermonomermortalitymouse modelnovelnovel drug classpathogenpathogenic funguspharmacologicprogramsresearch and developmentresistant strainscaffoldscreeningtherapeutically effectivetreatment strategy
项目摘要
SUMMARY
Invasive fungal infections (IFIs) create significant healthcare and economic burdens as they are responsible for
more than one billion infections worldwide each year resulting in more than 1.5 million deaths. Hospital patients
who acquire nosocomial IFIs experience longer hospital stays, increased morbidity, and higher mortality rates.
Only a few classes of antifungal drugs are available, and the emergence of resistance within all classes is an
alarming threat to global public health. Of particular concern are infections caused by Candida, Aspergillus,
Cryptococcus, and Pneumocystis species due the level of resistance seen with these pathogens and the
associated mortality rates. New classes of anti-fungals are desperately needed, particularly with the emergence
of multidrug resistant strains. To address this need, Curatix is developing a new class of anti-fungals that
disrupt an essential metabolic pathway and first step in coenzyme A (CoA) biosynthesis - the
phosphorylation of vitamin B5 by pantothenate kinase (PanK). Genetic and pharmacological studies
demonstrated that in fungi, this step is essential for cell viability, thus validating fungal PanKs as excellent targets
for the development of new classes of antifungal drugs. To achieve this goal, we conducted high-throughput
screen of ~156,593 compounds to search for inhibitors of A. fumigatus AfPanK and identified three 1st generation
compounds within a single chemotype with Ki values ranging between 190 and 360 nM. Screening and
preliminary medicinal chemistry optimization of 86 analogs identified four 2nd generation compounds with
improved activity against AfPanK as well as S. cerevisiae PanK (Cab1) with Ki values ranging between 12 and
170 nM for Cab1 and 50 and 217 nM for AfPanK. The compounds showed no cytotoxicity against five human
cell lines, very high selectivity for fungal PanKs over human PanKs (EC50 >10 µM), and significant biological
activity in vitro against C. albicans, C. parapsilosis and C. glabrata. We further solved the crystal structure of
Cab1 as an apo-enzyme and in complex with these inhibitors. This Phase I program will build upon these
significant data with the goal to evaluate the biological activity of these lead compounds in vivo and
initiate an SAR to improve their antifungal potency (>10 fold). In Aim 1 we will characterize the in vivo
efficacy of these compounds in animal models of candidiasis and aspergillosis. In Aim 2, we will build upon the
biological, biochemical and structural data to generate a library of analogs in order to identify compounds with
more potent activity against multiple fungal pathogens. Successful completion of the Phase I program will provide
the critical data needed to support a Phase II program focused on the efficacy of the lead compounds in various
models of fungal infections alone or in combination with other known antifungals. Clinical use of a PanK inhibitor
has the potential to provide a more effective therapeutic option for treating IFIs, both as monotherapy and in
combination with existing drugs, thus greatly decreasing the economic and healthcare burdens associated with
these infections and improving patient outcomes.
总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jae-Yeon Choi其他文献
Jae-Yeon Choi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
有機分子触媒を用いたAmphotericin Bの合成研究
有机分子催化剂合成两性霉素B的研究
- 批准号:
24K17671 - 财政年份:2024
- 资助金额:
$ 29.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EnLAmB - Enabling global access to affordable generic liposomal amphotericin B injectable formulations via advanced manufacturing technology
EnLAmB - 通过先进的制造技术,使全球能够获得负担得起的通用脂质体两性霉素 B 注射制剂
- 批准号:
MR/X014010/1 - 财政年份:2023
- 资助金额:
$ 29.4万 - 项目类别:
Research Grant
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
- 批准号:
559052-2021 - 财政年份:2022
- 资助金额:
$ 29.4万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Study on naturally-occurring peptides potentiating amphotericin B activity
天然存在的肽增强两性霉素 B 活性的研究
- 批准号:
22K05333 - 财政年份:2022
- 资助金额:
$ 29.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
- 批准号:
559052-2021 - 财政年份:2021
- 资助金额:
$ 29.4万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
- 批准号:
10024667 - 财政年份:2020
- 资助金额:
$ 29.4万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
9909193 - 财政年份:2020
- 资助金额:
$ 29.4万 - 项目类别:
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
- 批准号:
10248529 - 财政年份:2020
- 资助金额:
$ 29.4万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
10484014 - 财政年份:2020
- 资助金额:
$ 29.4万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
10654834 - 财政年份:2020
- 资助金额:
$ 29.4万 - 项目类别:














{{item.name}}会员




